Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...

Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...

Learn more about whether MKS Inc. or Marvell Technology, Inc. is a better investment based on AAII's A+ Investor grades, ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced ...

MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...

Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement ...

In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates ...

This framework enables quantitative predictions about how cellular systems convert frequency-encoded signals into precise ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Cavefish exhibit resilience to chronic sleep loss and tolerate elevated DNA damage and reduced DNA repair responses without compromising healthspan or longevity.

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...